Oxford BioMedica plc Board Change
— Appointment of New Non-Executive Director — Oxford, UK – 3 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford BioMedica Announces Collaboration With Immune Design Corp.
Oxford, UK and Seattle, WA, USA – 27 September 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, has signed a master services agreement with Immune Design Corp. (Immune Design), a… Read More
Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2012
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay… Read More
Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2012
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay… Read More
Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global Investment Conference
— 14th Annual Healthcare Conference — Oxford, UK – 29 August 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies
— Treatment of final RetinoStat® patient cohort underway — Oxford, UK – 08 August 2012: Oxford BioMedica plc (“Oxford BioMedica”… Read More
Oxford BioMedica Plc Announces Results of Firm Placing and Open Offer
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY… Read More
Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study
— Award of US$125,000 will support a second clinical site in Paris, France — Oxford, UK – 23 July 2012: Oxford BioMedica plc… Read More
Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer
— First patient treated at Cardiff University, Wales (UK) — Oxford, UK – 10 July 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company,… Read More
Oxford BioMedica Announces Notice of Posting of Prospectus
Click here to view the prospectus NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR… Read More
Oxford BioMedica Announces US$3 million Option Exercise Payment from Sanofi
— Sanofi acquires exclusive worldwide rights to develop and commercialise StarGen™ and UshStat® — Oxford, UK – 29 June… Read More
Oxford BioMedica Announces Proposed Firm Placing of £11 million and Open Offer of up to £5 million
Click here to read the full announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT… Read More